Can CAR T cell therapy stop severe rheumatoid arthritis?

In half of them, yes. Six people with severe rheumatoid arthritis that had stopped responding to drugs got a single CAR T cell infusion, and 3 of the 6 reached remission while taking no arthritis medication at all.

The trial is the phase 1 part of a study called COMPARE, published in Nature Medicine. All six patients had ACPA-positive rheumatoid arthritis, meaning their blood carried anti-citrullinated protein antibodies, the ones most closely tied to joint damage. All six were treatment-refractory, which means the standard drugs had already failed them.

CAR T cell therapy comes from cancer medicine. Doctors collect a patient’s own T cells, re-engineer them in a lab to hunt a specific target, and infuse them back. Here the target was CD19, a marker on the surface of B cells, the immune cells that make the antibodies driving rheumatoid arthritis. The idea is not to suppress those cells month after month, but to wipe them out once and let the immune system rebuild.

What the data show

Every patient in the trial improved. Their DAS28-CRP scores, a standard measure that combines 28 examined joints with a blood test for inflammation, fell by a median of 34% at the most recent follow-up. Three of the six hit outright remission on that score, and those same three also reached what rheumatologists call an ACR70 response, meaning at least a 70% improvement across a standard panel of arthritis measures. That happened after they had stopped all of their disease-modifying antirheumatic drugs.

The antibody results tracked the clinical ones. CD19-positive B cells disappeared from both blood and tissue, and autoantibody levels fell steadily afterward. Four of the six patients seroconverted for ACPAs against mutated citrullinated vimentin, meaning the antibody test that had been positive turned negative. Five of the six did the same for rheumatoid factor IgM. That is a deeper change than drug treatment usually produces, where antibodies typically persist even when symptoms are controlled.

Dr. Kumar’s Take

Six patients is six patients. This is a phase 1 safety trial with no control group and 36 to 52 weeks of follow-up, so nothing here tells us whether these remissions hold at three years or five.

The shape of the result is still notable. Rheumatoid arthritis treatment has been built on suppression: take the drug, hold the disease down, and it returns when you stop. Here the drugs were stopped first, and three people stayed in remission anyway. The antibody seroconversions suggest the immune system did not just calm down, it rebuilt with a different B cell population. Existing B cell drugs like rituximab do not usually manage that.

The counterweight is what it costs to get there. Patients received lymphodepletion chemotherapy before the infusion, and every one of them developed cytokine release syndrome. That is a burden no one would accept for a disease a weekly injection already controls. This is a therapy for people who have run out of options, and the trial was built for exactly that group.

Safety, limits, and caveats

The primary endpoints were the rate and severity of cytokine release syndrome, neurotoxicity, and adverse events in the first four weeks. Cytokine release syndrome happened in all six patients, but every case was grade 1 or 2, the milder end of the scale. No one developed immune effector cell-associated neurotoxicity syndrome, the brain-related complication that makes CAR T therapy risky in cancer care. There were no serious adverse events. One patient had a dose-limiting toxicity, a grade 3 rise in liver enzymes, which resolved with no lasting damage.

The trial met its primary endpoint on safety and has been cleared to move into phase 2. That is the honest description of where this sits: promising enough to keep testing, not established enough to change practice.

Practical takeaways

If you have rheumatoid arthritis that responds to methotrexate, a biologic, or a JAK inhibitor, this is not a treatment to ask for. The risk profile only makes sense when the standard options have failed.
If your arthritis is ACPA-positive and multiple drug classes have already stopped working, ask your rheumatologist whether any CAR T trial is enrolling near you. The phase 2 portion of this trial is the logical next home for patients like that.
Treat one-year remission in six people as a signal worth watching, not as proof of a cure. The durability question is still wide open.

FAQs

How is this different from rituximab, which also removes B cells?

Rituximab targets CD20, a marker found on most mature B cells but not on every stage of the B cell lineage. CD19 sits on a wider range of B cells, including some that CD20 drugs leave behind. Antibody drugs also circulate mainly in the bloodstream, while CAR T cells travel into tissue. In this trial, B cells were cleared from blood and tissue, and most patients turned antibody-negative. That kind of seroconversion is uncommon with standard B cell drugs, which is the main argument for testing the CAR T approach at all.

What does ACPA-positive mean, and does it matter?

ACPA stands for anti-citrullinated protein antibody, a blood marker found in most rheumatoid arthritis patients that usually signals a more aggressive form of the disease. Everyone in this trial was ACPA-positive, which was deliberate. If B cells making these antibodies drive the disease, then people who carry the antibodies are the group where removing those B cells should help most. It also means the findings say nothing about seronegative rheumatoid arthritis.

Why does every CAR T patient get cytokine release syndrome?

When the engineered T cells find their targets and start killing B cells, they release signaling chemicals called cytokines. A flood of those chemicals causes fever, low blood pressure, and flu-like illness. In cancer treatment, where there are far more target cells, this reaction can turn life-threatening. All six patients here had it, but every case stayed at grade 1 or 2, meaning fever and manageable symptoms rather than organ failure. It is best read as evidence the cells are working, at a cost that has to be monitored in hospital.

Bottom line

A single infusion of CD19-directed CAR T cells improved disease activity in all six patients with severe, drug-refractory, ACPA-positive rheumatoid arthritis, and put 3 of the 6 into remission with no arthritis medication over 36 to 52 weeks. Cytokine release syndrome was universal but mild, there was no neurotoxicity, and the one dose-limiting toxicity resolved. Six patients and a year of follow-up cannot tell us whether this is a durable reset or a long pause, but the signal is strong enough to justify phase 2.

Read the full study